Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132859 | 0.89 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL4005532 | 0.83 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL2204362 | 0.82 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL4003956 | 0.81 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL2205211 | 0.80 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL5261538 | 0.77 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL2204867 | 0.76 | CNR2 (0.79) | CNR2CNR1 | |
| Acetic Acid SCHEMBL15484451 | 0.75 | CNR2 (0.62) | CNR2CNR1 | |
| SCHEMBL3243572 | 0.75 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL4005558 | 0.74 | CNR2 (0.65) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-8372874-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| EP-2342199-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010036631-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.